



**Media Contact:**  
media@sklsi.com

### **SK life science to Showcase Scientific Data at the 2019 American Academy of Neurology Annual Meeting**

*-- Company will present four posters on cenobamate, an investigational antiepileptic drug*

**Paramus, New Jersey, May 3, 2019** – [SK Life Science, Inc.](#), a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative biopharmaceutical company focused on developing and bringing to market treatments for central nervous system (CNS) disorders, will present scientific data at the American Academy of Neurology Annual Meeting (AAN) in Philadelphia (May 4-10, 2019).

SK life science will present four posters on cenobamate, its lead investigational compound, at this year's meeting. New data will highlight the pharmacokinetics of cenobamate in renally impaired subjects, providing additional information that may be used in determining dosing for this subset of patients. Additionally, encore posters with data on the safety, efficacy, and mechanism of action of cenobamate, showcased at the American Epilepsy Society Annual Meeting in 2018, will also be presented.

"We look forward to sharing the results of our ongoing research with cenobamate, a potential treatment option for adults living with partial-onset seizures," said Marc Kamin, MD, chief medical officer, SK life science. "We remain committed to adult patients with epilepsy, many of whom still struggle to control their seizures and are at risk for serious and lifelong consequences as a result."

All posters will be presented on Sunday, May 5, from 11:30am - 6:30pm EST:

- *Poster P1.5-019: Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Multicenter, Open-Label Study*
- *Poster P1.5-032: Time to Onset of Efficacy in Seizure Reduction with Cenobamate (YKP3089) in Patients with Uncontrolled Partial Seizures From 2 Randomized Clinical Trials*
- *Poster P1.5-033: Effects of Cenobamate on GABA-A Receptor Modulation*
- *Poster P1.5-034: The Pharmacokinetics of Cenobamate in Special Populations*

#### **New campaign for healthcare providers will highlight consequences of continued seizures**

In addition to sharing their scientific findings, SK life science will also unveil a new epilepsy disease state education campaign for healthcare providers designed to highlight the consequences of continued seizures for patients and their caregivers. It seeks to increase awareness of and urgency to address the

reality that nearly 60% of epilepsy patients in the U.S. continue to have seizures<sup>i</sup>, despite the introduction of many new antiepileptic drugs over the last two decades.

“The goal of this campaign is to challenge healthcare providers to have more frequent and candid conversations with their patients to determine if their seizures are truly controlled, and if not, to motivate them to help patients reach their treatment goals,” said Sebby Borriello, chief commercial officer, SK life science.

Attendees at AAN are invited to see the campaign by visiting SK life science in booth #2245. The booth will feature an interactive challenge where attendees can compete to demonstrate their knowledge of the state of epilepsy care.

### **About Cenobamate**

Cenobamate (YKP3089) was discovered by SK Biopharmaceuticals and SK life science and is being investigated for the potential treatment of partial-onset seizures in adult patients.

Cenobamate’s mechanism of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.

Global trials for adults with partial-onset seizures are ongoing to evaluate cenobamate safety. Additional clinical trials are investigating cenobamate safety and efficacy in other seizure types.

The FDA accepted the filing of the New Drug Application for cenobamate for the potential treatment of partial-onset seizures in adults in February 2019. A Prescription Drug User Fee Act (PDUFA) target action date has been set for November 21, 2019. Cenobamate is not approved by the FDA or any other regulatory authorities. Safety and efficacy have not been established.

### **About SK life science**

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals, Co., Ltd., is focused on developing and commercializing treatments for disorders of the central nervous system (CNS). Both are a part of the global conglomerate SK Group, the second largest company in Korea. SK life science is located in Paramus, New Jersey.

We have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox-Gastaut syndrome and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize independently is cenobamate (YKP3089), an investigational compound for the potential treatment of partial-onset seizures in adult patients.

For more information, visit SK life science’s website at [www.SKLifeScienceInc.com](http://www.SKLifeScienceInc.com) and SK Biopharmaceuticals’ website at [www.skbp.com/eng](http://www.skbp.com/eng).

---

<sup>i</sup> Center for Disease Control and Prevention. Active Epilepsy and Seizure Control in Adults — United States, 2013 and 2015. [https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a1.htm?s\\_cid=mm6715a1](https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a1.htm?s_cid=mm6715a1) Accessed March 18, 2019